Murli Krishna Pharma is an API manufacturer based in India. It holds 9 active US drug master files across a filed portfolio of 8 molecules. Its GMP standing is certified by EMA. Customs aggregates show $19.0M of exports covering 349 molecules to 41 destinations in 2025.
| Site | FDA FEI |
|---|---|
| Ranjangaon Taluka Shirur, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Orlistat | US FDA | 2 |
| Clarithromycin | US FDA | 1 |
| Duloxetine | US FDA | 1 |
| Esomeprazole | US FDA | 1 |
| Itraconazole | US FDA | 1 |
| Lansoprazole | US FDA | 1 |
| Omeprazole | US FDA | 1 |
| Tacrolimus | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 1 | None |
| EMA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $4.7M | 17 |
| 2025 | Not reported | $19.0M | 41 |
| 2024 | Not reported | $13.4M | 32 |
| 2023 | Not reported | $14.9M | 33 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Murli Krishna Pharma comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.